Troglitazone

BreastfeedingPediatric
  • TRADE NAMES: Prelay (Sankyo); Rezulin (Pfizer)
  • INDICATIONS: Management of Type II diabetes (noninsulin-dependent diabetes mellitus (NIDDM) also known as adult-onset diabetes)
  • CLASS: Antidiabetic, CYP3A4 inducer, Thiazolidinedione
  • HALF-LIFE: 16–34 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Cholestyramine, Digoxin, Terfenadine

PREGNANCY CATEGORY: B

Troglitazone should not be used in Type I diabetes or for the treatment of diabetic keto-acidosis.

Not available in USA, UK or Japan.

HEPATOTOXICITY

See full prescribing information for complete boxed warning.

Our database has 19 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
RESPIRATORY
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top